Hemostasis based on a novel 'two-path unifying theory' and classification of hemostatic disorders

Blood Coagulation and Fibrinolysis

Volumn 29, Issue 7, 2018, Pages 573-584

  Chang, Jae C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

disseminated intravascular coagulation; disseminated intravascular microthrombosis; endotheliopathy; fibrinogenesis; macrothrombosis; microthrombogenesis; microthrombosis; thrombosis; unusually large von Willebrand factor multimers; vascular microthrombotic disease

Indexed keywords

VON WILLEBRAND FACTOR; THROMBOPLASTIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; DISEASE CLASSIFICATION; ENDOTHELIUM INJURY; EVT HEMORRHAGIC SYNDROME; FIBRIN CLOT; GENETIC DISORDER; HEMOSTASIS; HUMAN; MICROTHROMBUS; MUCOSAL HEMORRHAGIC SYNDROME; NONHUMAN; PATHOGENESIS; PETECHIAL SYNDROME; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE DISORDER; THROMBOPHILIA; BLOOD VESSEL; CLASSIFICATION; INJURIES; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

BLOOD VESSELS; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HEMOSTATIC DISORDERS; HUMANS; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

EID: 85055072846     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000765     Document Type: Article

References (68)

1. Gale AJ. Continuing education course #2: Current understanding of hemostasis. Toxicol Pathol 2011; 39:273-280.
2. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16:17-20.
3. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007; 120 (Suppl 1):S5-S9.
4. Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: Focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014; 25:206-216.
5. Mourik MJ, Valentijn JA, Voorberg J, Koster AJ, Valentijn KM, Eikenboom J. von Willebrand factor remodeling during exocytosis from vascular endothelial cells. J Thromb Haemost 2013; 11:2009-2019.
6. Preckel D, von Känel R. Regulation of hemostasis by the sympathetic nervous system: Any contribution to coronary artery disease?. Heartdrug 2004; 4:123-130.
7. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia 2008; 14 (Suppl 5):11-26.
8. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112:19-27.
9. Levi M, van der Poll T. A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost 2014; 40:874-880.
10. Naumann RO, Weinstein L. Disseminated intravascular coagulation - the clinician's dilemma. Obstet Gynecol Surv 1985; 40:487-492.
11. Chang JC. Thrombocytopenia in critically ill patients due to vascular microthrombotic disease: Pathogenesis based on 'two activation theory of the endothelium'. Vasc Dis Ther 2017; 2:1-7.
12. Chang JC. Viral hemorrhagic fevers due to endotheliopathy-associated disseminated intravascular microthrombosis and hepatic coagulopathy: Pathogenesis based on 'two activation theory of the endothelium'. Clin Microbiol Infect Dis 2017; 2:1-6.
13. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord 2015; 15:130.
14. Chauhan AK, Goerge T, Schneider SW, Wagner DD. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost 2007; 5:583-589.
15. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood 2013; 121:270-277.
16. Smith SA. State-of-the-art review. The cell-based model of coagulation. J Vet Emerg Crit Care (San Antonio) 2009; 19:3-10.
17. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009; 114:4886-4896.
18. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008; 111:651-657.
19. Stuart MJ, Walenga RW, Sadowitz PD, Maltby A, Kelton JG, Gauldie J. Bleeding time in hemophilia A: Potential mechanisms for prolongation. J Pediatr 1986; 108:215-218.
20. Eyster ME, Gordon RA, Ballard JO. The bleeding time is longer than normal in hemophilia. Blood 1981; 58:719-723.
21. Van Horn DL, Johnson SA. The mechanism of thrombocytopenic bleeding. Am J Clin Pathol 1966; 46:204-213.
22. Lobet S, Hermans C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. J Blood Med 2014; 5:207-218.
23. Qin HH, Xing ZF, Wang XF, Ding QL, Xi XD, Wang HL. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees. Blood Cells Mol Dis 2014; 52:181-185.
24. van Meegeren ME, Mancini TL, Schoormans SC, van Haren BJ, van Duren C, Diekstra A, et al. Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype. Haemophilia 2015; 21:e375-e383.
25. Zhu J, Guo WM, Yao YY, Zhao WL, Pan L, Cai X, et al. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 1999; 13:1062-1070.
26. Chu AJ. Tissue factor, blood coagulation, and beyond: An overview. Int J Inflam 2011; 2011:367284.
27. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009; 108:1447-1452.
28. Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R, et al. Tissue factor positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost 2016; 14:153-166.
29. Mann KG, Krudysz-Amblo J, Butenas S. Tissue factor controversies. Thromb Res 2012; 129 (Suppl 2):S5-S7.
30. Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. Tissue factor in thrombosis and hemorrhage. Surgery 2007; 142 (4 Suppl):S2-S14.
31. Kretz CA, Vaezzadeh N, Gross PL. Tissue factor and thrombosis models. Arterioscler Thromb Vasc Biol 2010; 30:900-908.
32. Rauch U, Nemerson Y. Circulating tissue factor and thrombosis. Curr Opin Hematol 2000; 7:273-277.
33. Manly DA, Boles J, Mackman N. Role of tissue factor in venous thrombosis. Annu Rev Physiol 2011; 73:515-525.
34. Tadros GM, Broder K, Bachour F. Intracoronary macrothrombus formation during percutaneous coronary intervention despite optimal activated clotting time using bivalirudin - a case report. Angiology 2005; 56: 761-765.
35. Giblett JP, Hoole SP. Remote ischemic conditioning in elective PCI?. J Cardiovasc Pharmacol Ther 2017; 22:310-315.
36. Oweida SW, Roubin GS, Smith RB 3rd, Salam AA. Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. J Vasc Surg 1990; 12:310-315.
37. Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011; 13:1-16.
38. Lipe B, Ornstein DL. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation 2011; 124:e365-e368.
39. Patnaik MM, Moll S. Inherited antithrombin deficiency: A review. Haemophilia 2008; 14:1229-1239.
40. Jen J, Cohen AH, Yue Q, Stout JT, Vinters HV, Nelson S, Baloh RW. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49:1322-1330.
41. Kleffner I, Duning T, Lohmann H, Deppe M, Basel T, Promesberger J, et al. A brief review of Susac syndrome. J Neurol Sci 2012; 322:35-40.
42. Magro CM, Poe JC, Kim C, Shapiro L, Nuovo G, Crow MK, Crow YJ. Degos disease: A C5b-9/interferon-a-mediated endotheliopathy syndrome. Am J Clin Pathol 2011; 135:599-610.
43. Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J 2018; August 11. [In press].
44. Chang JC. Disseminated intravascular coagulation (DIC): Is it fact or fancy?. Blood Coagul Fibrinolysis 2018; 29:330-337.
45. Chang JC. Molecular pathogenesis of STEC-HUS caused by endothelial heterogeneity and unprotected complement activation, leading to endotheliopathy and impaired ADAMTS13 activity: Based on twoactivation theory of the endothelium and vascular microthrombotic disease. Nephrol Renal Dis 2017; 2:1-8.
46. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91:1-19.
47. Levi M, van der Poll T. Disseminated intravascular coagulation: A review for the internist. Intern Emerg Med 2013; 8:23-32.
48. Sugita Y, Masuho Y. CD59: Its role in complement regulation and potential for therapeutic use. Immunotechnology 1995; 1:157-168.
49. Ehrlenbach S, Rosales A, Posch W, Wilflingseder D, Hermann M, Brockmeyer J, et al. Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 2013; 81:2678-2685.
50. Camous L, Veyradier A, Darmon M, Galicier L, Mariotte E, Canet E, et al. Macrovascular thrombosis in critically ill patients with thrombotic microangiopathies. Intern Emerg Med 2014; 9:267-272.
51. McKay DG. Disseminated intravascular coagulation: An intermediary mechanism of disease. New York, NY: Hoeber Medical Division of Harper and Row; 1965.
52. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2 Suppl):S26-S34.
53. Gando S, LeviM, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016; 2:16037.
54. Wada H, Matsumoto T, Hatada T. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol 2012; 5:643-652.
55. Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost 2013; 11 (Suppl 1):277-284.
56. Versteeg HH, Ruf W. Thiol pathways in the regulation of tissue factor prothrombotic activity. Curr Opin Hematol 2011; 18:343-348.
57. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96:170-175.
58. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417-430.
59. PetäjäJ. Inflammation and coagulation. An overview. Thromb Res 2011; 127 (Suppl 2):S34-S37.
60. Demetz G, Ott I. The interface between inflammation and coagulation in cardiovascular disease. Int J Inflam 2012; 2012:860301.
61. Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99:1019-1029.
62. Killian M, Bruel Tronchon N, Maillard N, Tardy B. A diagnosis of haemolyticuraemic syndrome blurred by alcohol abuse. BMJ Case Rep 2014; 2014:pii: Bcr2014205940.
63. Panackel C, Thomas R, Sebastian B, Mathai SK. Recent advances in management of acute liver failure. Indian J Crit Care Med 2015; 19:27-33.
64. Lim YS. Acute liver failure in Korea: Etiology, prognosis and treatment. Korean J Hepatol 2010; 16:5-18.
65. McKay DG. Progress in disseminated intravascular coagulation. II. Calif Med 1969; 111:279-290.
66. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992; 6:1247-1257.
67. Carr JM. Disseminated intravascular coagulation in cirrhosis. Hepatology 1989; 10:103-110.
68. Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 12:7725-7733.